Crespo Javier, Martínez-González José, Rius Jordi, Badimon Lina
Centro de Investigación Cardiovascular, CSIC/ICCC, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret # 167, 08025 Barcelona, Spain.
Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
Our aim was to investigate whether neuron-derived orphan receptor-1 (NOR-1), an early gene induced by low density lipoproteins (LDL) in vascular smooth muscle cells (VSMC), is regulated by statins.
NOR-1 expression was analyzed in human VSMC in culture and in vivo in the aorta of diet-induced hyperlipemic pigs by RT-PCR and real-time PCR. [3H]Thymidine incorporation was used as an index of DNA synthesis. NOR-1 promoter activity was analyzed using a luciferase reporter system. Cyclic AMP response element binding protein (CREB) binding was assessed by EMSA and ELISA and CREB activation (phosphorylation in Ser133) by Western blotting.
Simvastatin inhibited NOR-1 expression induced by LDL in VSMC and by hypercholesterolemia in the abdominal aorta of hyperlipemic pigs. The inhibition of the isoprenylation of geranylgeranylated proteins by simvastatin was key in both NOR-1 up-regulation and DNA synthesis induced by LDL. Inhibitors of RhoA (toxin B and exotoxin C3) and ROCK (Y-27632) mimicked the effect of simvastatin on NOR-1. Similarly both simvastatin treatment and cells transfected with a RhoA dominant-negative (RhoAT19N) showed inhibition of LDL-induced NOR-1 promoter activity. These effects were associated to the interference of the activation of CREB, a key transcription factor involved in NOR-1 induction. Finally, simvastatin prevented LDL induction of a reporter construct containing four consensus CRE and inhibited the expression of SMemb (a marker for dedifferentiated VSMC) dependent on CREB.
NOR-1 is a target for simvastatin in the vascular wall. We identified NOR-1 and CREB as key transcription factors mediating the effect of statins on VSMC proliferation through a mechanism dependent on RhoA/ROCK.
我们的目的是研究神经元衍生的孤儿受体-1(NOR-1),一种由血管平滑肌细胞(VSMC)中低密度脂蛋白(LDL)诱导的早期基因,是否受他汀类药物调控。
通过RT-PCR和实时PCR分析培养的人VSMC以及饮食诱导的高脂血症猪主动脉中的NOR-1表达。[3H]胸苷掺入用作DNA合成指标。使用荧光素酶报告系统分析NOR-1启动子活性。通过电泳迁移率变动分析(EMSA)和酶联免疫吸附测定(ELISA)评估环磷酸腺苷反应元件结合蛋白(CREB)结合情况,并通过蛋白质印迹法评估CREB激活(Ser133磷酸化)。
辛伐他汀抑制VSMC中LDL诱导的NOR-1表达以及高脂血症猪腹主动脉中高胆固醇血症诱导的NOR-1表达。辛伐他汀对香叶基香叶基化蛋白异戊烯化的抑制在NOR-1上调和LDL诱导的DNA合成中均起关键作用。RhoA抑制剂(毒素B和外毒素C3)和ROCK抑制剂(Y-27632)模拟了辛伐他汀对NOR-1的作用。同样,辛伐他汀处理和用RhoA显性阴性(RhoAT19N)转染的细胞均显示出对LDL诱导的NOR-1启动子活性的抑制。这些作用与关键转录因子CREB激活的干扰有关,CREB参与NOR-1诱导。最后,辛伐他汀阻止了含有四个共有CRE的报告构建体的LDL诱导,并抑制了依赖于CREB的SMemb(去分化VSMC的标志物)的表达。
NOR-1是血管壁中辛伐他汀的作用靶点。我们确定NOR-1和CREB是通过依赖于RhoA/ROCK的机制介导他汀类药物对VSMC增殖作用的关键转录因子。